Apellis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,105	1,004	781.37	396.59	75.42	66.56
Revenue Growth (YoY)	42.46%	28.46%	97.02%	425.83%	13.31%	-73.44%
Cost of Revenue	108.42	102.24	117.72	58.51	5.64	0.2
Gross Profit	996.86	901.55	663.64	338.08	69.79	66.36
Selling, General & Admin	545.24	550.27	501.05	500.82	277.16	176.77
Research & Development	286.39	295.85	327.57	354.39	387.24	345.87
Other Operating Expenses	-	-	-	-	-	80
Total Operating Expenses	831.64	846.12	828.62	855.2	664.4	602.64
Operating Income	165.22	55.43	-164.98	-517.12	-594.61	-536.28
Interest Income	13.4	13.14	12.77	20.93	8.91	0.42
Interest Expense	-43.6	-44.33	-40.39	-29.58	-32.63	-13.24
Other Non-Operating Income (Expense)	0.27	-0.13	-4.12	-0.73	-33.18	-196.9
Total Non-Operating Income (Expense)	-29.93	-31.32	-31.74	-9.38	-56.89	-209.73
Pretax Income	135.3	24.11	-196.72	-526.5	-651.5	-746
Provision for Income Taxes	1.88	1.72	1.16	2.13	0.67	0.35
Net Income	270.6	22.39	-197.88	-528.63	-652.17	-746.35
Net Income to Common	270.6	22.39	-197.88	-528.63	-652.17	-746.35
Shares Outstanding (Basic)	127	126	124	119	106	84
Shares Outstanding (Diluted)	129	130	124	119	106	84
Shares Change (YoY)	3.99%	4.80%	4.40%	11.84%	25.70%	12.32%
EPS (Basic)	1.06	0.18	-1.60	-4.45	-6.15	-8.84
EPS (Diluted)	1.04	0.20	-1.60	-4.45	-6.15	-8.84
Shares Outstanding	127.92	126.62	124.5	119.56	110.77	97.52
Free Cash Flow	37.47	45.01	-88.27	-595.51	-515.27	-564.23
Free Cash Flow Growth	-16.77%	-	-	-	-	-
Free Cash Flow Per Share	0.29	0.35	-0.71	-5.02	-4.86	-6.68
Gross Margin	90.19%	89.81%	84.93%	85.25%	92.53%	99.70%
Operating Margin	14.95%	5.52%	-21.11%	-130.39%	-788.38%	-805.67%
Profit Margin	24.48%	2.23%	-25.32%	-133.29%	-864.70%	-1121.27%
FCF Margin	3.39%	4.48%	-11.30%	-150.16%	-683.18%	-847.66%
EBITDA	166.63	56.99	-163.18	-515.34	-593.06	-534.79
EBITDA Margin	15.08%	5.68%	-20.88%	-129.94%	-786.32%	-803.43%
EBIT	165.22	55.43	-164.98	-517.12	-594.61	-536.28
EBIT Margin	14.95%	5.52%	-21.11%	-130.39%	-788.38%	-805.67%
Effective Tax Rate	1.39%	7.14%	-0.59%	-0.40%	-0.10%	-0.05%

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q